TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02397356
Drug: Placebo first BA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised saline 1-2ml
Study: NCT03591575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid solution that matches deferiprone oral solution in appearance and taste
Study: NCT01313962
Drug: Flufirvitide-3 0.05 mg single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray
Study: NCT01313962
Drug: Flufirvitide-3, 0.1 mg single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray
Study: NCT01313962
Drug: Flufirvitide-3, 0.2 mg single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal spray
Study: NCT01313962
Drug: Flufirvitide-3, 0.4 mg single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray
Study: NCT01345682
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly
Study: NCT03072173
Drug: placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
Study: NCT01686568
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00496301
Drug: Gemcitabine, Capecitabine and Sorafenib (6 cycles)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
Study: NCT02032654
Drug: Placebo (for flucloxacillin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
Study: NCT00156169
Drug: Dunaliella
Normalized name: DUNALIELLA SALINA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01458028
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of 20 mg BAY85-3934 as tablet
Study: NCT01458028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
Study: NCT02622646
Drug: Recombinant VIII factor
Normalized name: factor VIII Injection [Recombinate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Study: NCT00150020
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03200613
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
Study: NCT01910064
Drug: GK530G
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01680003
Drug: Hepar-P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01680003
Drug: Placebo for Hepar-P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01110187
Drug: Fosphenytoin
Normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
Study: NCT02704403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01838044
Drug: Placebo and celecoxib
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.
Study: NCT01908595
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03838484
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo skin patch will be applied to the skin.
Study: NCT02287818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily from Day 1 to Week 12
Study: NCT01844856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV to maintain the blind.
Study: NCT02531165
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
Study: NCT03596450
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
Study: NCT01601210
Drug: Creatine monohydrate or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2g, 4g, and 10g of creatine monohydrate
Study: NCT02531165
Drug: Unfractioned Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.
Study: NCT02460224
Drug: LAG525
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAG525 was administered via intravenous (i.v.) infusion
Study: NCT02460224
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 was administered via i.v. infusion
Study: NCT02138357
Drug: Placebo for BTDS patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo patch will be manufactured to mimic the BTDS patch.
Study: NCT00006056
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006056
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01703793
Drug: Test Product 49778
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01703793
Drug: Test Product 10156
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01812928
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01523080
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release Gel tabs 650 mg
Study: NCT01124981
Drug: Haemocomplettan® P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
Study: NCT00187070
Drug: Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT00885300
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin 1000iu/ml as catheter lock at the end of hemodialysis
Study: NCT00290667
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00844792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day with meals.
Study: NCT00290667
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02908529
Drug: Placebo, 2 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 tablets 2 hours before sleep
Study: NCT00630929
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg oral tablet 3 times daily with meals for 6 weeks
Study: NCT00630929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo orally for 6 weeks
Study: NCT00630929
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Study: NCT01051401
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03929835
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1/C20 CBD
Study: NCT03929835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil with chlorophyl
Study: NCT03925051
Drug: Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: mAb targeting RANKL. human monoclonal antibody targeting RANKL.
Study: NCT03925051
Drug: CMAB807
Approvals — FDA: no, EMA: no, PMDA: no
Description: human monoclonal antibody targeting RANKL.
Study: NCT03330184
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02623504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage to match active treatment by mouth twice daily in the morning and in the evening.
Study: NCT00468988
Drug: Travatan® Z
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00468988
Drug: Xalatan®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02937766
Drug: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00097812
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00068094
Drug: Probiotic-containing powder
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04497987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT00682019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00740623
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 14 weeks
Study: NCT00491920
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
Study: NCT03689712
Drug: GC4419 90mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 minute IV infusion
Study: NCT03689712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 minute IV infusion
Study: NCT02510911
Drug: Caffeine (100 mg)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
Study: NCT02510911
Drug: Caffeine (200 mg)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
Study: NCT02515201
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin in central venous catheter lumen
Study: NCT04065633
Drug: Comm-Fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg PF-04965842 commercial tablet formulation under fed conditions
Study: NCT03266172
Drug: GSK2982772 Modified Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
Study: NCT03266172
Drug: GSK2982772 Immediate Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
Study: NCT02907749
Drug: Spironolactone and carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with carvedilol in combination with spironolactone.
Study: NCT00976534
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg, capsules, oral, during 3 weeks
Study: NCT00976534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, oral, during 3 weeks
Study: NCT01203358
Drug: Exosurf
Normalized name: Exosurf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants received up to four intratracheal doses of the surfactant.
Study: NCT00994591
Drug: Pharmacokinetic dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
Study: NCT02203955
Drug: Short-Chain Fructooligosaccharide
Normalized name: fructooligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 chews (8.0 g scFOS) orally for 12 months
Study: NCT00413010
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + concurrent GAD treatment from the open-label study period
Study: NCT04494724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT02475616
Drug: PCO371
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02475616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02663141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00019474
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01360177
Drug: Na134I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 to 150 mCi
Study: NCT03764267
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain
Study: NCT00958035
Drug: vehicle sterile solution (placebo)
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply one drop of study medication along the upper eyelid margin once daily in the evening
Study: NCT01693432
Drug: DS (docetaxel+S-1)
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will be delivered as a 3-week cycle.~1. Docetaxel 60 mg/m²IV on day 1~2. S-1 80 mg/m2/day PO on day 1-14
Study: NCT01114100
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
Study: NCT03764267
Drug: general anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
Study: NCT01384058
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg per day for six weeks
Study: NCT01384058
Drug: Ezetimibe 10/Simvastatin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
Study: NCT04259684
Drug: gases Nitric Oxide (gNO)
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the intervention group will receive gNO blended into the fresh gas flow of the cardiopulmonary bypass (CPB) oxygenator and maintained at 20 ppm via an Ikaria INO Max DSIR (Mallinckrodt Pharmaceuticals, St. Louis, Missouri, USA), with continuous sampling of NO and NO2 concentration from a port adjacent to the oxygenator. The gNO delivery will be initiated when the patient is on CPB and stopped once the patient comes off CPB.
Study: NCT00549770
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00549770
Drug: AHU377
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00549770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00648297
Drug: Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80/5mg, single dose fed
Study: NCT00648297
Drug: Corzide® Tablets 80 mg/5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80/5mg, single dose fed
Study: NCT02436512
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes
Study: NCT04577690
Drug: Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
Study: NCT04577690
Drug: Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only
Approvals — FDA: no, EMA: no, PMDA: no
Description: The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
Study: NCT02137187
Drug: Optimized drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized drug therapy for heart failure and atrial fibrillation rate control
Study: NCT00000252
Drug: 0% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000252
Drug: 10% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000252
Drug: 20% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000252
Drug: 30% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000252
Drug: 40% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03688555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo hard gelatin capsules
Study: NCT02803996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
Study: NCT03337724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
Study: NCT03077165
Drug: S42909 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study: NCT03077165
Drug: S42909 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study: NCT03077165
Drug: S42909 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study: NCT03077165
Drug: S42909 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
Study: NCT03077165
Drug: S42909 1200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
Study: NCT01275014
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
Study: NCT04737096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03436173
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 10 mg/2.5 ml mixed with water